

# Grand Rounds

Friday, June 14, 9:00am

## Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer

*featuring*

**Barbara Burtness, MD**

**Anthony N. Brady Professor of Medicine (Medical  
Oncology); Chief Translational Research Officer, Yale  
Cancer Center; Chief, Head and Neck Cancers/Sarcoma**

55 Park Street Auditorium | [Zoom](#) Access

Continental breakfast will be available

**Needs:** There have been many advancements in how molecular biology has allowed us to treat cancer and there is a need to discuss how synthetic lethal therapy is being used for HPV-Negative head and neck cancer.

**Objectives:** Discuss synthetic lethal therapeutic strategies in HPV-negative head and neck cancer. Share advances in molecular biology to better treat patients with head and neck cancers.



Dr. Burtness is internationally recognized for her research in head and neck cancer. She is a Professor of Medicine (Medical Oncology), Chief Translational Research Officer, and Associate Cancer Center Director for Translational Research and serves as Co-Leader of the Developmental Therapeutics Program, is Division Chief for Head and Neck/Sarcoma Oncology, and is Director of the Yale Head and Neck SPORE.

Dr. Burtness chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee and the ECOG-ACRIN Task Force for the Advancement of Women, and leads national and international trials of targeted therapy in head and neck cancer. Her lab studies synthetic lethal therapeutic strategies in head and neck cancer and the targeting of aurora kinase A to overcome adaptive resistance to EGFR inhibition and direct KRAS inhibition in lung cancer.